In conclusion, daratumumab can inhibit the expression levels of IL-6, IL-2, IL-10, and TNF-α in patients with multiple myeloma, thereby inhibiting the growth of multiple myeloma. This evidence concerns the gene IL6 and AL amyloidosis.